Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Purdue Pharma LP |
---|---|
Information provided by: | Purdue Pharma LP |
ClinicalTrials.gov Identifier: | NCT00315874 |
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system and immediate release oxycodone/acetaminophen in subjects with chronic low back pain inadequately treated with non-opioid analgesics. The double-blind treatment intervention duration is 60 days.
Condition | Intervention | Phase |
---|---|---|
Back Pain |
Drug: Buprenorphine transdermal delivery system |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Safety and Efficacy of Buprenorphine TDS (Transdermal Delivery System) 5, 10 and 20 Applied Every 7 Days for Sixty Days Vs. 5 Mg Oxycodone/325 Mg Acetaminophen Tablets q6h Prn Vs. Placebo in Patients With Chronic Low Back Pain |
Estimated Enrollment: | 225 |
Study Start Date: | April 1997 |
Estimated Study Completion Date: | January 1998 |
Buprenorphine is a synthetic opioid analgesic with over twenty-five years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain. Transdermal systems may offer advantages over currently indicated oral products including ease and convenience of use, improved compliance, possible reduction in patient care, and prolonged and consistent delivery of drug.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-specific exclusion/inclusion criteria may apply.
United States, Arizona | |
Arizona Research & Education | |
Phoenix, Arizona, United States, 85012 | |
Hawthorne & York, Intl, Ltd | |
Phoenix, Arizona, United States, 85008 | |
United States, Florida | |
Gainesville Clinical Research Center | |
Gainesville, Florida, United States, 32605 | |
Park Place Therapeutic Center | |
Plantation, Florida, United States, 33324 | |
United States, Georgia | |
Atlanta Research Center | |
Atlanta, Georgia, United States, 30033 | |
United States, Indiana | |
Rheumatology Associates, Inc. | |
Indianapolis, Indiana, United States, 46260 | |
United States, Michigan | |
Westside Family Medical Center | |
Kalamazoo, Michigan, United States, 49009 | |
United States, Missouri | |
The Center for Pharmaceutical Research | |
Kansas City, Missouri, United States, 64114 | |
United States, New York | |
The New York Hospital Cornell Medical Center | |
New York, New York, United States, 10021 | |
United States, North Carolina | |
NC Clinical Research, Inc. | |
Raleigh, North Carolina, United States, 27607 | |
Pain Control Ctr Bowman Gray School of Med | |
Winston-Salem, North Carolina, United States, 27103 | |
United States, Texas | |
Metroplex Clinical Research Center | |
Dallas, Texas, United States, 75235 |
Study ID Numbers: | BP96-0102 |
Study First Received: | April 18, 2006 |
Last Updated: | April 29, 2006 |
ClinicalTrials.gov Identifier: | NCT00315874 |
Health Authority: | United States: Food and Drug Administration |
chronic back pain opioid transdermal |
Signs and Symptoms Buprenorphine Oxycodone Neurologic Manifestations |
Low Back Pain Pain Back Pain Acetaminophen |
Sensory System Agents Therapeutic Uses Narcotic Antagonists Physiological Effects of Drugs Nervous System Diseases Central Nervous System Depressants |
Narcotics Peripheral Nervous System Agents Analgesics Central Nervous System Agents Pharmacologic Actions Analgesics, Opioid |